PMID- 28672883
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 5
IP  - 3
DP  - 2017 Jun 26
TI  - Role of alphabeta T Cell Depletion in Prevention of Graft versus Host Disease.
LID - 10.3390/biomedicines5030035 [doi]
LID - 35
AB  - Graft versus host disease (GVHD) represents a major complication of allogeneic 
      hematopoietic stem cell transplantation (allo HCT). Graft cellular manipulation 
      has been used to mitigate the risk of GVHD. The alphabeta T cells are considered the 
      primary culprit for causing GVHD therefore depletion of this T cell subset 
      emerged as a promising cellular manipulation strategy to overcome the human 
      leukocyte antigen (HLA) barrier of haploidentical (haplo) HCT. This approach is 
      also being investigated in HLA-matched HCT. In several studies, alphabeta T cell 
      depletion HCT has been performed without pharmacologic GVHD prophylaxis, thus 
      unleashing favorable effect of donor's natural killer cells (NK) and gammadelta T cells. 
      This article will discuss the evolution of this method in clinical practice and 
      the clinical outcome as described in different clinical trials.
FAU - Abdelhakim, Haitham
AU  - Abdelhakim H
AD  - Division of Hematology and Oncology, University of Kansas Cancer Center, Kansas 
      City, KS 66205, USA. habdelhakim@kumc.edu.
FAU - Abdel-Azim, Hisham
AU  - Abdel-Azim H
AD  - Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's 
      Hospital Los Angeles, University of Southern California Keck School of Medicine, 
      Los Angeles, CA 90027, USA. habdelazim@chla.usc.edu.
FAU - Saad, Ayman
AU  - Saad A
AD  - Section of Blood and Marrow Transplantation and Cellular Therapy, University of 
      Alabama at Birmingham, Brimingham, AL 35294, USA. asaad@uabmc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170626
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC5618293
OTO - NOTNLM
OT  - graft versus host disease
OT  - haploidentical transplant
OT  - alphabeta T cells
COIS- Ayman Saad declares Royalty for licensing of intellectual property (Incysus 
      Biomedical), grant support (American Porphyria foundation), consultant fees 
      (Actinium Pharma Inc, New York, NY, USA), Research support (Astellas and Fate 
      Therapeutics), and Honoraria (Alexion and Spectrum Pharmaceutical). Other authors 
      have no conflict of interest.
EDAT- 2017/07/05 06:00
MHDA- 2017/07/05 06:01
PMCR- 2017/06/26
CRDT- 2017/07/05 06:00
PHST- 2017/05/23 00:00 [received]
PHST- 2017/06/15 00:00 [revised]
PHST- 2017/06/18 00:00 [accepted]
PHST- 2017/07/05 06:00 [entrez]
PHST- 2017/07/05 06:00 [pubmed]
PHST- 2017/07/05 06:01 [medline]
PHST- 2017/06/26 00:00 [pmc-release]
AID - biomedicines5030035 [pii]
AID - biomedicines-05-00035 [pii]
AID - 10.3390/biomedicines5030035 [doi]
PST - epublish
SO  - Biomedicines. 2017 Jun 26;5(3):35. doi: 10.3390/biomedicines5030035.